Actively Recruiting
Evaluating Safety and Effects of Two Strengths of ZYG24004 Cream for Adults With Tinea Pedis Caused by Dermatophytes
Led by Sinomune Pharmaceutical Co., Ltd · Updated on 2026-08-04
64
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a multicenter, randomized, double-blind, placebo-controlled Phase 1b trial to evaluate the safety, local tolerability, and pharmacokinetics of two concentrations 1% and 3% of ZYG24004 topical cream in adults with tinea pedis caused by dermatophytes. The study also explores preliminary efficacy through clinical and mycological assessments. Participants have clinically diagnosed tinea pedis with lesions mainly in the interdigital area and a positive fungal microscopy test. The study involves four sequential cohorts escalating from lower to higher concentrations and from one to two administrations. Each cohort includes 16 participants randomized in a 31 ratio to receive either ZYG24004 cream or a placebo. The cream is applied topically at approximately 2 g per foot either once on Day 1 or twice on Day 1 and Day 8. Safety and tolerability reviews occur after each cohort completes dosing, and pharmacokinetic sampling is conducted through Day 15 or Day 22 depending on the dosing schedule. Participants will be assessed for safety, tolerability, and pharmacokinetics throughout the study, with preliminary efficacy evaluated by fungal cure rates and symptom scores up to Day 43. Visits include clinical evaluations, local tolerability assessments, and plasma sampling for drug concentration. The trial lasts about six weeks per participant, with frequent monitoring to capture adverse events and treatment responses.
CONDITIONS
Brief Title
A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes
Research Team
Y
Yaheng Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here